• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open‐label, blinded–end‐point trial
ConclusionsEarly reduction of BP with valsartan did not reduce death or dependency and major vascular events at 90 days, but increased the risk of END.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Mi Sun Oh, Kyung‐Ho Yu, Keun‐Sik Hong, Dong‐Wha Kang, Jong‐Moo Park, Hee‐Joon Bae, Jaseong Koo, Juneyoung Lee, Byung‐Chul Lee, Tags: Research Source Type: research

Predictors of Stroke in Patients With Impaired Glucose Tolerance: Results From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial Brief Reports
Conclusions— The most powerful predictors of stroke in patients with impaired glucose tolerance included a combination of established risk factors and novel variables, such as previous venous thromboembolism and elevated waist circumference, allowing moderately effective identification of high-risk individuals.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Preiss, D., Giles, T. D., Thomas, L. E., Sun, J.-L., Haffner, S. M., Holman, R. R., Standl, E., Mazzone, T., Rutten, G. E., Tognoni, G., Chiang, F.-T., McMurray, J. J. V., Califf, R. M. Tags: Cerebrovascular disease/stroke, Risk Factors, Glucose intolerance Brief Reports Source Type: research